The U.S. Food and Drug Administration (FDA) granted a supplemental efficacy approval for Tecentriq (atezolizumab) on October 2, 2025. This approval, designated BLA 761034 S-58, signifies the FDA's acceptance of new efficacy data for the drug, which is developed by Genentech Inc.
Background
Atezolizumab, known commercially as Tecentriq, is a drug developed by Genentech Inc. The nature of this supplemental application indicates that Tecentriq has received prior approvals from the FDA.
What this means
This supplemental efficacy approval for Tecentriq (atezolizumab) signifies that the FDA has reviewed and accepted new data demonstrating the drug's effectiveness. While the specific indication for this supplemental approval is not detailed in the provided information, such approvals typically expand the drug's approved uses, refine its application in an existing indication, or update its label based on new clinical evidence of efficacy. This reinforces the drug's overall profile and its role in patient treatment.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 761034 S-58, concerning Tecentriq (atezolizumab), was documented on October 2, 2025, on accessdata.fda.gov.